Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of ZoomInfo Technologies, Inc. related to misrepresentation of the company's financial and operational results due to the effects of the COVID-19 pandemic [1] Summary by Relevant Sections Financial Misrepresentation - ZoomInfo's financial results were allegedly inflated by temporary demand increases during the COVID-19 pandemic, leading to a misrepresentation of the company's actual performance [1] - The lawsuit claims that ZoomInfo's reported revenues, operating income, and customer retention metrics were materially overstated [1] Customer Base Concerns - A significant portion of ZoomInfo's existing customers were reportedly attempting to reduce their usage or abandon the product altogether [1] - The company allegedly employed manipulative auto-renew policies and threats of litigation to retain customers against their will, damaging customer relationships and competitive advantages [1] Future Implications - The coercive tactics used by ZoomInfo are said to have created a hidden demand cliff for future customer contract renewals, indicating potential challenges in sustaining revenue growth [1]

Core Viewpoint - The Ademi Firm is investigating HilleVax for potential breaches of fiduciary duty and other legal violations related to its transaction with XOMA Royalty Corporation [1] Transaction Details - HilleVax shareholders will receive $1.95 per share in cash along with contingent value rights (CVR) that may provide additional payments based on HilleVax's remaining cash above $102.95 million, savings from Boston office lease obligations, and proceeds from the sale of the company's norovirus vaccine programs within specified timeframes [2] - HilleVax insiders are set to receive substantial benefits as part of the change of control arrangements [2] Investigation Focus - The transaction agreement imposes significant penalties on HilleVax for accepting competing bids, which may limit competing transactions unreasonably [3] - The investigation is centered on the conduct of HilleVax's board of directors and whether they are fulfilling their fiduciary duties to all shareholders [3]